Health Catalyst (NASDAQ:HCAT) reported quarterly sales of $59.63 million which beat the analyst consensus estimate of $56.81 million by 4.96 percent. This is a 37.84 percent increase over sales of $43.26 million the same period last year.
SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $6
SVB Leerink analyst Mani Foroohar maintains Abeona Therapeutics (NASDAQ:ABEO) with a Market Perform and raises the price target from $5 to $6.
